Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18764637 | 0.85 | KIF11 (0.53) | KIF11 | |
| SCHEMBL18764634 | 0.85 | KIF11 (0.53) | KIF11 | |
| SCHEMBL1526445 | 0.80 | KIF11 (0.57) | KIF11 | |
| SCHEMBL12944446 | 0.79 | KIF11 (0.52) | KIF11 | |
| SCHEMBL9106215 | 0.77 | KIF11 (0.63) | KIF11 | |
| SCHEMBL18764694 | 0.77 | KIF11 (0.49) | KIF11 | |
| SCHEMBL18764574 | 0.77 | KIF11 (0.49) | KIF11 | |
| SCHEMBL18764571 | 0.77 | KIF11 (0.49) | KIF11 | |
| SCHEMBL10315008 | 0.76 | KIF11 (0.52) | KIF11 | |
| SCHEMBL17258330 | 0.76 | KIF11 (0.52) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896048-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | Bayer Pharmaceuticals Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006121588-A2 | PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006091506-A2 | NEUROPEPTIDE Y4 RECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | WO | disclosed |